Technology

The latest innovations are in focus at the 127th annual meeting of the American Academy of Ophthalmology, being held at the Moscone Center in San Francisco.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.

Developing technology may offer marked improvements in surgical precision

Physicians explore how other specialties adopted and integrated remote monitoring into plans.

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

Earlier this year, the US Centers for Disease Control and Prevention issued an advisory, sounding the alarm for an outbreak of a drug resistant strain of the bacteria Pseudomonas aeruginosa that was connected to the use of artificial tears.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.

Noncontact esthesiometry screens for all levels of neurotrophic keratitis.

According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.

Study demonstrates power of IRIS Registry for evaluation of safety, efficacy

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss if Artificial Intelligence is ready for the clinic and the emergency room

According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.

The Icahn School of Medicine at Mount Sinai opened the Center for Ophthalmic Artificial Intelligence and Human Health, which is dedicated to advancing artificial intelligence to offer faster diagnosis and treatment.

Orbis International physician spotlights the latest trends for cataract surgery training.

Kaushal Solanki, PhD, discusses how ophthalmologists can now use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy.

Researchers are involved in the development of Eye2Gene, an AI system capable of identifying the genetic cause of IRDs from retinal scans.

Scientists hope to develop of novel AI solutions for the prediction of DPN using corneal OCT images.

IIT Kanpur licensed the technology to Reliance Life Sciences Pvt. Ltd. and this marks the first time a gene therapy related technology has been developed and transferred from an academic institution to a company in India.

According to the company, its latest laser recently received FDA clearance and CE mark approval.

Debate continues over the best way to apply the treatment option.